MT Newswires
Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating
📈
AI Sentiment
Highly Positive
8/10
Revolution Medicines Inc. News
Latest updates and market news for RVMD
13 news
Feb 21 - Feb 27, 2026
Page 1
MT Newswires
Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here’s Why
📈
AI Sentiment
Highly Positive
9/10
Zacks
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
📉
AI Sentiment
Negative
3/10
Insider Monkey
Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment?
📊
AI Sentiment
Positive
6/10
GlobeNewswire
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Is Revolution Medicines (RVMD) Share Price Lagging Behind Its Long Term Surge?
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout
📈
AI Sentiment
Highly Positive
9/10
Share this news page